Introduction 48
Neuroendocrine tumours (NET) are relatively rare and heterogeneous tumours that arise 49 from neuroendocrine cells, often arising in the gastrointestinal (GI) tract, lung, and 50 pancreas. 1 The World Health Organization (WHO) classifies lung and thymic NET into four 51 major subtypes: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine 52 carcinoma, and small cell carcinoma. 2 53
Given the lack of prospective clinical trial data from large numbers of patients with advanced 54 lung and thymic carcinoids, the majority of treatment recommendations are based on results 55 of studies in GI NET and mixed primary NET populations that include lung and thymic 56 carcinoids 3,4 ; until recently, there has been an absence of approved drugs for this indication. 4 57
Based on the results of the phase 3 RADIANT-4 study, the mammalian target of rapamycin 58
(mTOR) inhibitor everolimus recently received US Food and Drug Administration (FDA) and 59
European Medicines Agency (EMA) approval for the treatment of patients with advanced 60 (unresectable, locally advanced, or metastatic), progressive, well-differentiated, non-61 functional NET of lung and GI origin, in addition to the previous approval in pancreatic 62 NET. 5, 6 In RADIANT-4, median progression-free survival (PFS) of patients with advanced, 63 well-differentiated NET of GI or lung origin was significantly improved: 11·0 months for 64 patients receiving everolimus, compared with 3·9 months among patients receiving placebo 65 (hazard ratio [HR] 0·48; 95% confidence interval [CI] 0·35-0·67; p<0·0001). 7 In a subgroup 66 analysis of patients with advanced lung carcinoids, everolimus improved median PFS by 5·6 67 months vs placebo (9·2 vs 3·6 months), as assessed by central review. 8 68 Current European Neuroendocrine Tumor Society (ENETS) consensus guidelines 69 recommend everolimus as a first-line therapy for progressive, advanced lung carcinoids, 70 unless a somatostatin analogue (SSA; long-acting octreotide or lanreotide) may be 71 considered as first-line therapy for tumours with low proliferative activity (i.e., TC) and 72 somatostatin receptor (SSTR) expression on imaging. 4 The recommendation for SSA 73 treatment is based on the expectation that TC will respond in a similar manner to grade 1 74 6 NET of other sites, such as the GI tract, 4 as well as data from a few retrospective analyses 75 of lung NET. 9 76
Pasireotide is a novel multireceptor ligand SSA with higher affinity for somatostatin receptors 77 1 (SSTR1), 3 (SSTR3), and 5 (SSTR5) compared with octreotide, but a slightly lower affinity 78 for SSTR2. 10 The antitumour activity of pasireotide (long-acting or short-acting 79 subcutaneous) has been investigated in phase 2 and 3 trials of patients with advanced NET 80 who have symptoms refractory to standard long-acting octreotide dosing, 11,12 along with a 81 phase 2 trial of treatment-naive patients with metastatic grade 1 or 2 NET. 13 It is 82 hypothesised that the combined action of long-acting pasireotide on SSTR and inhibition of 83 insulin-like growth factor 1 receptor (IGF-1R), along with the mTOR inhibitor everolimus, may 84 control tumour growth more effectively than either treatment alone. 14 85
The phase 2 LUNA trial aimed to assess the efficacy and safety of long-acting pasireotide 86 and everolimus, administered alone or in combination, in patients with advanced carcinoids 87 of the lung or thymus. LUNA is the first prospective, randomised clinical trial to focus 88 exclusively on this specific patient population. 89 90
Methods

91
Study design and participants 92
LUNA was a prospective, single-stage, multicentre, randomised, open-label, phase 2 trial 93 conducted at 36 centres across nine countries (appendix, p 1). The study comprised a 12-94 month core study period, followed by an extension phase that continued until all patients had 95 progressed. Adult patients (aged >18 years) with pathologically confirmed advanced 96 (unresectable or metastatic), well-differentiated, TC or AC of the lung or thymus were 97 eligible. Histopathologic classification was determined using the WHO 2004 classification of 98 tumours of the lung, pleura, thymus, and heart; 15 cytology by endobronchial ultrasound-99 guided fine needle aspiration alone was not sufficient for classification. Patients of any 100 treatment line (naive or pre-treated) and progressive within 12 months according to 101 7 Response Evaluation Criteria In Solid Tumours, version 1·1 (RECIST v1·1) were eligible. 102
Additional key inclusion criteria included: measurable disease according to computed 103 tomography (CT) scan or magnetic resonance imaging (MRI) as defined by RECIST v1·1; 104 WHO performance status ≤2; and adequate bone marrow, liver, and kidney function. Due to 105 the potential for other SSA or mTOR inhibitors to interfere with the antitumour efficacy 106 observed in this study, patients were ineligible if they had any of the following: severe 107 functional disease (ie, carcinoid syndrome) requiring symptomatic treatment with SSA 108 (judgement made by study clinicians); previous treatment with any long-acting SSA within 1 109 month of randomisation; or treatment with mTOR inhibitors (sirolimus, temsirolimus, or 110 everolimus). Patients were also ineligible if they had any of the following: radiotherapy within 111 4 weeks of randomisation; Cushing's syndrome requiring treatment within 3 months; 112 radioligand therapy (peptide receptor radionuclide therapy) within 6 months of 113 randomisation; hepatic artery embolisation, cryoablation, or radiofrequency ablation of 114 hepatic metastasis within 3 months of randomisation; participation in a clinical trial testing an 115 investigational drug within 4 weeks or 5 half-lives (whichever is longer) of randomisation; 116 uncontrolled diabetes mellitus (haemoglobin A1C of at least 8%) despite adequate therapy; 117 presence of active or suspected acute or chronic uncontrolled infection; or signs of 118 recurrence of previous or concomitant malignancies within the last 3 years or requiring active 119 treatment. The estimated life expectancy of eligible patients was 24-40 months. 1,16 120
The study was conducted in accordance with Good Clinical Practice, the ethical principles of 121 the Declaration of Helsinki, and local regulations. Institutional review boards, independent 122 ethics committee, and the research ethics board reviewed and approved the study and all 123 amendments to the protocol. All patients provided written informed consent. Further details 124 of the protocol are available on clinicaltrials.gov. 125
126
Randomisation and masking 127
Patients were randomised (1:1:1) to receive long-acting pasireotide monotherapy (P arm), 128 everolimus monotherapy (E arm), or everolimus and long-acting pasireotide in combination 129 8 (EP arm). The planned number of patients enrolled was 120, with 40 patients randomised to 130 each treatment arm. At the screening visit, the investigator or their designee assigned a 131 unique number to each patient being considered for the study. Once the eligibility of each 132 patient was confirmed, the investigator or their designee registered the patient using an 133 interactive voice recognition system into one of the three treatment arms. The randomisation 134 allocation sequence was generated by an external company (Perceptive Informatics, 135
Nottingham, UK). Patients were stratified by TC vs AC according to the WHO classification 136 and line of study treatment (first line of systemic medical treatment vs other). Patients and 137 investigators were not masked to treatment allocation. 138 139
Procedures 140
Patients randomised to the P arm received long-acting pasireotide at a dose of 60 mg 141 intramuscularly (IM) every 28 days; patients randomised to the E arm received everolimus at 142 a dose of 10 mg taken orally (PO) once daily (QD); and patients randomised to the EP arm 143 received everolimus and long-acting pasireotide at a dose of 10 mg everolimus PO QD and 144 60 mg long-acting pasireotide IM every 28 days. Dose reductions and treatment interruptions 145 for less than 56 days for long-acting pasireotide and less than 28 days for everolimus were 146 allowed for patients who did not tolerate therapy, or to manage treatment-related adverse 147 events (AEs). Two dose reductions were allowed for everolimus: from 10 mg per day to 5 mg 148 per day, with a subsequent reduction to 5 mg every other day. A dose reduction from 60 mg 149 to 40 mg long-acting pasireotide every 28 days was allowed with a subsequent, but 150 transient, reduction to 20 mg. Re-escalation to 40 mg was required within 56 days; 151 otherwise, the patient was discontinued from study. 152
All patients who underwent randomisation were locally assessed for efficacy by triphasic CT 153 or MRI every 3 months for the duration of the treatment phase (12 months) and, if the patient 154 continued into the extension phase, every 3 months thereafter. Safety was monitored by 155 assessing haematology (baseline and weeks 2, 4, and every 4 weeks (q4w) from weeks 8-156 52), coagulation (weeks 0, 4, 8, and every 8 weeks (q8w) from weeks 12-52; additionally at 3 157 9 and 7 weeks for those treated with pasireotide), biochemistry (weeks 0, 2, 4, and q4w from 158 weeks 8-52), fasting glucose (weeks 0, 2-4, and q4w from weeks 7-52), liver function tests 159 (weeks 0, 2, 4, and q4w from weeks 8-52; additionally at 3 and 7 weeks for those treated 160 with pasireotide), serum lipid profile (weeks 2, 4, and q4w from weeks 8-52), thyroid function 161 test (weeks 12, 24, and 52), urinalysis (weeks 0, 2, 4, and q4w from weeks 8-52), 162 chromogranin-A and 5-hydroxyindoleacetic acid measurement (weeks 12, 24, 36, 48, and 163 52), electrocardiogram (weeks 0, 3, 8, 16, 28, 40, and 52), gallbladder assessment (only 164 those treated with pasireotide; weeks 12, 24, 36, 48, 52), and WHO performance status and 165 vital signs (weeks 0, 2, 4, and q4w from weeks 8-52). Adverse events were assessed 166 continuously throughout the study and were evaluated for severity grade and duration, 167 suspected relationship to treatment, whether a dose adjustment, interruption, or 168 discontinuation was required, outcome, and whether concomitant medication was required. 169
Study treatment continued for 12 months or until disease progression, intolerable toxicity, 170 start of new cancer therapy, withdrawal of consent, or discontinuation for any other reason. 171
Patients who demonstrated clinical benefit, and who were not experiencing unacceptable 172 toxicity, were allowed to continue treatment in an extension phase until disease progression, 173 intolerable toxicity, start of new cancer therapy, withdrawal of consent, or discontinuation for 174 any other reason. The end of the study was defined as the final study visit 2 years after the 175 start of the last randomised patient, or when all patients had progressed (whichever came 176 first). All patients were requested to participate in a safety follow-up 56 days after their last 177 dose of study treatment to assess AEs. 178 179
Outcomes 180
The primary efficacy endpoint was the progression-free rate at month 9, defined as the 181 proportion of patients with overall response at month 9, including complete response (CR), 182 partial response (PR), or stable disease (SD) according to local RECIST v1·1. Patients with a 183 missing or unknown tumour assessment at month 9, and with CR, PR, or SD at month 11 or 184 12, were considered as progression free at month 9. Patients with no tumour assessment 185 performed in the 211-294 study day period (9 month window) were classified as not 186 assessed at month 9. Patients with progressive disease, not assessed, or unknown response 187 at month 9 were classified as non-progression free. 188
Overall PFS, defined as the time from first study drug administration to tumour progression or 189 death from any cause according to RECIST v1·1, was a secondary endpoint. Patients who 190 did not experience a PFS event were censored at the date of the patient's last adequate 191 tumour assessment. The probability of patients remaining event free (i.e., no objective 192 tumour progression or death from any cause) up to the specified timepoint were obtained 193 from the Kaplan-Meier survival estimates for all treatment groups; the Greenwood formula 194 was used for confidence intervals of Kaplan-Meier estimates. Tumour shrinkage was 195 evaluated according to best response per RECIST v1·1. 196
The safety and tolerability of long-acting pasireotide and everolimus alone or in combination 197 was assessed by measuring the rate and severity of AEs, which were assessed according to 198 the Common Terminology Criteria for Adverse Events (CTCAE) version 4·0 (CTCAE grade 5 199
[death] was not used in this study). The relationship of AEs to treatment was assessed per 200 investigator decision. 201 202
Statistical analysis 203
All randomised patients who received at least one dose of study drug constituted the full 204 analysis set (FAS). Following the intention-to-treat principle, patients were analysed 205 according to the treatment and stratum they were assigned to at randomisation. Primary 206 efficacy analyses were assessed on the FAS. The safety set included all patients who 207 received at least one dose of study drug and had at least one post-baseline safety 208
assessment. 209
For the primary endpoint, a Fleming single-stage design was employed for each treatment 210 arm, where p 0 (the null hypothesis) represents the highest proportion of patients progression 211 free at 9 months that indicated the treatment is clearly ineffective, and p 1 (the alternative 212 hypothesis) represented the minimum required proportion of patients who were progression 213 11 free to show that the treatment is effective. The trial tested the null hypothesis H 0 that the 214 observed proportion of patients who were progression free, p, was less than or equal to p 0 215 against the alternative hypothesis H 1 that p was greater than or equal to p 1 . It consisted of 216 entering a predetermined number of patients and deciding in favour of p 0 or p 1 based on the 217 success rate observed by using an appropriate cutoff between p 0 and p 1 . If the number of 218 responses was greater than or equal to R+1, p 0 was rejected. If the number of responses 219 was less than or equal to R, p 1 was rejected. In this trial, p 0 and p 1 were set equal to 0·20 220 and 0·45, respectively, and target alpha and beta were 5% and 10%, respectively. The 221 number of patients required per treatment arm to determine whether the proportion 222 responding was less than or equal to p 0 or greater than or equal to p 1 was determined to be 223 40. If the number of responses was 13 or more, the hypothesis that p ≤ p 0 =20% was rejected 224 with a target alpha error rate of 5% and an actual alpha error rate of 4·3%; if the number of 225 responses was 12 or less, the hypothesis that p ≥ p 1 =45% was rejected with an actual beta 226 error rate of 4%. No dropout percentage was considered in this calculation. 227
The 95% confidence interval (CI) for the progression-free rate at 9 months was computed 228 using an exact binomial method. PFS was estimated using the Kaplan-Meier method, with a 229 95% CI. Tumour shrinkage data were presented as waterfall plots by treatment arm. All data 230 were analysed using SAS version 9.4. 231
An independent data monitoring committee reviewed safety-related issues and provided 232 oversight in study conduct. This study was registered with the EU Clinical Trials Register, 233
number EudraCT 2011-002872-17, protocol CSOM230DIC03, and with ClinicalTrials.gov, 234 number NCT01563354. 235 236
Role of the funding source 237
The study was designed by academic investigators and representatives of the funder 238 (Novartis Pharma AG). The first draft of the report was prepared by PF, GG, NS, MS, KÖ, 239 EB, and a medical writer employed by the funder. All authors vouch for the accuracy and 240 completeness of the data and attest that the study conformed to the protocol and statistical 241 12 analysis plan. The corresponding author had full access to all data in the study and had final 242 responsibility, along with KÖ and EB, for the decision to submit for publication. which were more frequently reported in the long-acting pasireotide treatment arm. 263
Prior therapies are presented in the appendix (p 2). Approximately a third (40/124; 32·3%) of 264 patients were treated for advanced disease in the first line. Prior SSA use was well balanced 265 among the treatment groups; 48·4% (60/124) of patients had received prior SSAs, with the 266 length of SSA exposure ranging from less than 6 months to 5 or more years. Prior 267 antineoplastic therapy was more frequently reported in the EP arm. 268
13
During the core 12-month treatment phase, 65·3% (81/124) of randomised patients 269 discontinued treatment, mainly due to AEs (n=33) and disease progression (n=33) (figure 1). 270
In the P arm, 68·3% (28/41) of patients discontinued treatment, with 18/28 due to disease 271 progression and 5/28 due to AEs as the primary reason. In the E arm, 64·3% (27/42) 272 discontinued treatment, with 15/27 due to AEs as the primary reason and 7/27 due to 273 disease progression. In the EP arm, 63·4% (26/41) discontinued treatment, with 13/26 due 274
to AEs as the primary reason and 8/26 due to disease progression. Of the 43 patients who 275 completed the core phase of the study, 41 entered the extension phase (figure 1). 276
The proportions of patients with overall lesion assessment at month 9 being CR, PR, or SD 277 according to RECIST v1·1 (i.e., progression-free) in the P arm, E arm, or EP arm were 16/41 278 (39·0%; 95% CI 24·2-55·5), 14/42 (33·3%; 95% CI 19·6-49·5), and 24/41 (58·5%; 95% CI 279 42·1-73·7), respectively (table 2). As noted in table 2, the minimum number of patients 280 required to be progression free at month 9 in order to consider the treatment as effective 281 was 13 patients for the P arm, 14 patients for the E arm, and 13 patients for the EP arm. 282
Overall lesion response at month 9 was mostly SD among the 3 treatment groups; 34·1% 283 (14/41) in the P arm, 31·0% (13/42) in the E arm, and 48·8% (20/41) in the EP arm. 284
Progressive disease at 9 months was observed in 7/41 (17·1%), 1/42 (2·4%), and 0/41 (0%) 285 patients in the P arm, E arm, or EP arm, respectively. Patients with progressive disease, not 286 assessed, or unknown response at month 9 were classified as non-progression free. The 287
proportions of patients with no tumour assessment performed at 9 months were classified as 288
'not assessed' but were not excluded from the analysis; 18/41 (43·9%), 25/42 (59·5%), and 289 17/41 (41·5%) in the P arm, E arm, or EP arm, respectively. This was mostly due to AEs 290 leading to withdrawal in 3/41 (7·3%), 15/42 (35·7%), and 10/41 (24·4%) of those in the P 291 arm, E arm, and EP arm, respectively, or due to disease progression prior to month 9 tumour 292 assessment in 10/41 (24·4%), 4/42 (9·5%), and 2/41 (4·9%), respectively. Overall, 11/36 293 (30·6%) patients in the P arm, 16/33 (48·5%) in the E arm, and 24/33 (72·7%) in the EP arm 294 experienced some degree of tumour shrinkage ( figure 2) . 295
14
The median PFS by investigator-assessed radiological review was 8·51 months (95% CI 296 5·68-not estimable [NE]), 12·48 months (95% CI 5·55-NE), and 11·79 months (95% CI 297 11·10-NE) in the P arm, E arm, and EP arm, respectively (figure 3). The probability of 298 patients remaining event-free (i.e., no objective tumour progression or death from any 299 cause) until 9 months (table 3) was 49·6% (95% CI 31·9-65·1) for those in the P arm, 56·9% 300 (95% CI 38·1-71·9) in the E arm, and 79·2% (95% CI 61·1-89·5) in the EP arm. 301
During the core treatment phase, median patient exposures to long-acting pasireotide in the 302 P arm and everolimus in the E arm were 38·9 weeks (interquartile range [IQR] 20·00-52·14) 303
and 26·9 weeks (IQR 10·43-52·00), respectively. In the EP arm, median patient exposure to 304 long-acting pasireotide was 48·4 weeks (IQR 12·57-52·14) and 49·0 weeks (IQR 12·14-305 52·14) to everolimus; the median exposure to both drugs combined was 49·0 weeks (IQR 306 12·57-52·14). The median relative dose intensity of long-acting pasireotide was 100% in 307 both the P arm (IQR 97·1%-102·0%) and EP arm (IQR 89·2%-107·1%). The median 308 relative dose intensity of everolimus was 93·6% (IQR 63·0%-100·0%) and 84·1% (IQR 309 53·6%-100·0%) in the E arm and EP arm, respectively. 12-month treatment phase or up to 56 days after the last study treatment exposure date: 349 2/41 (4·9%) in the P arm, 6/42 (14·3%) in the E arm, and 3/41 (7·3%) in the EP arm. In the P 350 arm, one patient died of disease progression and one died due to pneumonia. Neither death 351 16 was suspected to be related with pasireotide treatment. In the E arm, five deaths were not 352 considered related to study drug: two due to disease progression and one each due to 353 respiratory failure, pneumonia, and cardiac failure. One patient died of acute kidney injury 354 associated with diarrhoea, which was considered related to everolimus therapy. In the EP 355 arm, one death due to disease progression was not considered related to study drug. One 356 patient died from diarrhoea and urinary sepsis which was suspected to be associated with 357 everolimus and one patient died due to acute renal failure and also respiratory failure. For 358 the latter patient, acute renal failure was not suspected to be related with study treatment, 359 while respiratory failure was suspected to be related to everolimus. 360 361
Discussion
362
To our knowledge, LUNA is the first prospective, randomised clinical trial dedicated 363 specifically to patients with advanced carcinoid tumours of the lung and thymus, 364 demonstrating the feasibility of conducting clinical trials in this rare NET subpopulation. 365
Results of the current phase 2 study suggest that long-acting pasireotide, everolimus, or 366 combination therapy with both agents is associated with antitumour activity, as the null 367 hypothesis was rejected for all three treatment arms. The 2-year extension phase of this trial 368 is ongoing, with all patients who benefited from treatment at 12 months; mature data on PFS 369 will be available when the extension phase of the trial is completed. 370
To date, the clinical investigation of exclusive pulmonary NET patient populations have been 371 limited to small retrospective studies. 9,17-19 Subgroup analyses of mixed NET populations 372 have also been conducted, with everolimus being the most studied drug in the setting of lung 373
NETs. 8, 20 In the current study, the patient population enrolled had relatively aggressive 374 tumours; 68·5% of patients were classified as having AC, 67·7% were post first-line therapy, Results-Medicare database) revealed that carcinoid syndrome was present in 8·0% 382 (83/1044), 7·9% (19/239), and 15·3% (30/196) of localised, regional, and distant stage 383 disease. 21 Previous estimates of carcinoid syndrome in lung carcinoids have been much 384 lower (2%) and carcinoid syndrome is rare in thymic carcinoids. 22 Other functional 385 syndromes observed in thoracic carcinoids include Cushing syndrome, caused by ectopic 386 adrenocorticotropic hormone production, with an incidence of 2% in bronchial carcinoids and 387 up to 50% in thymic carcinoids, and acromegaly, which occurs rarely in both bronchial and 388 thymic carcinoids and is caused by ectopic growth hormone-releasing hormone. 22 389
The 'conservative' 9-month timepoint was selected to assess the primary endpoint in this 390 study in order to minimise bias; this timepoint was considered to be acceptable based on the 391 clinical experience and known biological behaviour of lung NET at the time of study design. 392
In addition, uncertainties surrounding the management of pulmonary NET with these novel 393 agents, along with the unknown rate and evolution of functioning syndromes in this NET 394 subpopulation, were taken into account. Long-acting pasireotide has previously been investigated in clinical trials of patients with 409 advanced, grade 1 or 2 NET, primarily in patients with primary tumours of the small intestine 410 or pancreas, with a median PFS of 11·0-11·8 months reported for monotherapy. 12, 13, 23 In this 411 study of patients with lung or thymic carcinoids, the median PFS of patients treated with 412 long-acting pasireotide monotherapy was 8·5 months and the combination of everolimus and 413 long-acting pasireotide was associated with a median PFS of 11·8 months. In the phase 2 414 COOPERATE-2 study, the addition of long-acting pasireotide to everolimus did not 415 significantly improve median PFS vs everolimus in patients with non-functional pancreatic 416 NET (16·8 vs 16·6 months, respectively; hazard ratio 0·99; 95% CI 0·6-1·5, p=0·49). 417
However, combined treatment with everolimus and long-acting pasireotide demonstrated a 418 trend toward a higher objective response rate-20·3%, vs 6·2% treated with everolimus 419 monotherapy. 23 420
The most common grade 1/2 AEs with a suspected relationship to treatment with long-acting 421 pasireotide monotherapy or everolimus and long-acting pasireotide were diarrhoea (36·6% 422 and 46·3%) and hyperglycaemia (41·5% and 65·9%). Most AEs were manageable through 423 dose modification or interruption, with no new safety signals being reported in this study. The 424 safety profiles observed in the monotherapy and the combination treatment arms were 425 similar to that of previous studies, 8, 11, 24 indicating the feasibility of combination therapy with 426 long-acting pasireotide and everolimus. Although discontinuations due to AEs and dose 427 modifications were frequently reported, the median relative dose intensity remained high in 428
all treatment groups. Hyperglycaemia has been observed as an AE in other studies with 429 everolimus and pasireotide monotherapy, albeit at lower frequencies. 8, 11 The high levels of 430 hyperglycaemia reported in a phase 1 study 24 and in our study of everolimus and long-acting 431 pasireotide in combination, appears to indicate an additive effect, highlighting the importance 432 of close monitoring of fasting serum glucose. Achievement of optimal glycaemic control 433 before initiation of therapy is required. 25 Hyperglycaemia is, however, manageable in the 434 19 context of a multidisciplinary centre, thus avoiding the need for treatment discontinuation, 435 particularly in patients responding to treatment. 25 The everolimus dose may be reduced to 5 436 mg/day or interrupted until the fasting serum glucose has normalized, as per the protocol 437 used in this study; however, considering the high number of treatment interruptions (52·4%) 438 or dose reductions (61·1%) due to AEs in this study, it is difficult to state definitively whether 439 hyperglycaemia will be manageable in all patients without exploratory analyses of the dose- This study has a number of limitations. The small size and lack of a placebo control arm 446 limits the comparisons, and the conclusions of the study should be considered exploratory. 447
No subanalyses of efficacy by primary site (lung vs thymus), carcinoid subtype (TC vs AC), 448
Ki-67 index (high vs low), or median time from radiological disease progression at baseline 449 were performed, which may have provided useful information in this rarely studied 450 population. However, these subanalyses were not appropriate, given the small sample size 451 and imbalance between groups (eg, only 8 patients with thymic carcinoids), or were not 452 possible due to the lack of recorded time from disease progression at baseline or Ki-67 453 indices for each patient. Ki-67 indices were not reported for each patient because the 454 pathologic assessment in this study was based on the 2004 WHO classification of tumours 455 of the lung and thymus, which did not include Ki-67. 15 It would have been unethical to select 456 patients based on Ki-67, since the 2004 WHO classification was the only clinical method 457 recognized by regulatory authorities for the classification of thoracic NET at the time of 458 enrolment. Another limitation of the study is that only 43/124 (34·7%) patients completed the 459 12-month core treatment phase. However, the completion and discontinuation rates were 460 consistent across the treatment groups (figure 1). For the primary endpoint, a single-stage 461 20 Fleming design was employed for each treatment arm; this design has no provision for early 462 termination if the observed response rate is unacceptably low. Furthermore, for the primary 463 endpoint (progression-free rate at 9 months), ideally a Kaplan-Meier analysis should be 464 employed rather than the responder and non-responder analysis that was performed in this 465 study. In this study, it was not appropriate to alter the primary endpoint to a Kaplan-Meier 466 analysis after patients had been recruited because the sample size was determined based 467 on the responder and non-responder analysis. The handling of missing data, such as 468 patients with a missing tumour assessment at 9 months being classified as non-progression 469 free, may have led to an underestimation of tumour response rates included in the analysis 470 of the primary endpoint. However, exclusion of these patients from the primary endpoint 471 analysis would have led to bias in the results by selecting patients who likely had improved 472
outcomes. In addition, the lack of blinded central radiological review of tumour response may 473 have introduced bias in the assessment of response. 474
In summary, the treatment of patients with advanced carcinoid tumours of the lung and 475 thymus with long-acting pasireotide alone or in combination with everolimus showed 476 preliminary evidence of efficacy and an acceptable safety profile. Further studies would be 477 needed to confirm the antitumour efficacy of combination therapy consisting of an SSA with 478 everolimus in this subset of patients with NET. Future research may improve prognostic 479 stratification, identify predictors of response, and determine the anti-secretory impact of the 480 treatment combination of an SSA with everolimus in the thoracic NET setting. While beyond 481 the scope of this study, the process toward personalized and precision medicine will be a 482 priority over the next two decades. 483 *Overall lesion response at month 9 is the investigator-reported overall lesion response at the week 36 visit. The 95% CI for the responses are computed using an exact binomial method. †If progression is not documented and one or more lesions have not been assessed or have been assessed using a different method from baseline, then the overall lesion response at month 9 is 'unknown'. ‡If a patient does not have any tumour assessments made in the study day 211-294 window, then the overall lesion response at month 9 is 'not assessed'. §The progression-free rate at month 9 is defined as the proportion of patients with overall lesion assessment at month 9 being CR, PR, or SD according to Response Evaluation Criteria in Solid Tumours, version 1·1. Patients with missing or unknown month 9 assessment and with CR, PR, or SD at any of the following assessments at month 11 or 12 are considered as progression free at month 9. ǁH 0 : a progression-free rate ≤20% is the null hypothesis on the progression-free rates at month 9. The minimum number of progression-free patients to reject H 0 is calculated according to the Fleming single-stage design. *Presented for those with grade 1 or 2 adverse events occurring with a frequency of ≥10% in at least one treatment group.
1 Percentages are calculated based on n (number of patients included in the analysis).
Figure Legends
Contradiction refers to a percentage change in target lesion available, but contradicted by overall lesion response (progressive disease). † N is the number of randomised patients; n is the number of patients with valid postbaseline assessments, excluding patients for whom target lesion and overall response is 'unknown'. 
